ASND
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Ascendis Pharma receives positive CHMP opinion for once-weekly TransCon CNP (navepegritide) to treat achondroplasia in childrenOct 16, 2026
- Eyconis initiated its first-in-human clinical trial of EYC-0305 in treatment-naive patients with wet age-related macular degenerationAug 18, 2026
- Ascendis reported Week 78 COACH results and provided updates on its achondroplasia programs and U.S. uptake of YUVIWELAug 6, 2026
- Week 52 COACH trial data showed TransCon hGH enhanced benefits of TransCon CNP beyond growth in achondroplasiaApr 8, 2026
- New pooled 3-year analysis confirms sustained, clinically meaningful improvements in renal function for TransCon® PTH (Palopegteriparatide)-treated adults with hypoparathyroidismNov 7, 2025